glp-1 with medicaid Rhode Island considers ending coverage of drugs for weight loss • Rhode Island Current Did you know? Approximately 36%

And there may be some people previously unresponsive to existing therapies who would benefit from trying orforglipron instead

The ongoing dedicated ophthalmic trial named as FOCUS study, which aims to evaluate semaglutides long-term effects on diabetic retinopathy, is now ongoing and could contribute to a comprehensive understanding of the true risk-benefit profile of these agents in patients with or at risk for diabetic retinopathy (NCT03811561) [104]

August 2023, abgerufen am 21

2023, McIntyre, Roger S

The transition requires careful dose management to avoid side effects

The most common reported side effects are gastrointestinal, especially nausea, diarrhea, constipation, and vomiting